Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...
Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...
Bertrand Y. Tuan, MD, hematologist/oncologist at Pacific Hematology Oncology Associates and California Pacific Medical Center ...
AnemiaPhone, a technology developed by a multidisciplinary team of Cornell researchers to accurately, quickly and cheaply assess iron deficiency, has ...
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis ...
The 2023 AABB guidelines overall favor a restrictive transfusion strategy, recommending RBC transfusion for hemoglobin <7 ...
The outlay, plus up to $1.1 billion in milestones, has secured Takeda ex-China rights to a molecule that could compete with ...
Study finds annual healthcare costs per patient are significantly higher than previously described– HHT costs are higher than other ...
Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial milestone payments ...
Verywell Health on MSN2d
The Surprising Truth About Spinach's Iron ContentSpinach has iron, calcium, and phosphorus, micronutrients essential to a well-rounded diet. Learn how many milligrams of iron ...
Following a phase 1b trial, the potent and selective dual inhibitor of IRAK1 and IRAK4 received fast track designation for the treatment of patients with lower-risk myelodysplastic syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback